Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Serum
Use
The test is useful for the differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy. It evaluates AP3B2 (adaptor protein 3 beta2)-IgG by cell-binding assay using serum specimens. AP3B2 (adaptor protein 3 beta2)-IgG is a marker of an autoimmune disorder unified by gait instability as the predominant neurologic presentation. Patients present with either cerebellar, dorsal column, or sensory neuronal dysfunction. Clinical improvement following treatment has been reported. AP3B2 autoimmunity appears rare, is accompanied by ataxia (sensory or cerebellar), and is potentially treatable.
Special Instructions
Not provided.
Limitations
A positive result supports a diagnosis of neurological autoimmunity. However, a negative result does not exclude neurological autoimmunity or cancer. Neurological phenotypes encountered include cerebellar ataxia, spinocerebellar ataxia, myelopathy, sensory neuronopathy, and autonomic neuropathy. Neurological stabilization or improvement may occur with immune therapy, but not all patients may respond to treatment. The test has not been cleared or approved by the FDA and is consistent with CLIA requirements. Interfering substances and improper specimen collection may lead to diagnostic confusion.
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
AP3B2
Protein
LOINC Codes
- 101907-4 - AP3B2 IgG Spec Ql
- 101907-4 - AP3B2 IgG Spec Ql
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |